Clinical trials: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC
This is a multicenter, open-label Phase I study evaluating the safety, tolerability, pharmacokinetic, and efficacy of Intravenous HS-20093 in combination with ZG006 with or without adebrelimab in patients with extensive-stage…
- Trial name
- NCT07892625
- Testing
- HS-20093 for Injection, ZG006, Adebrelimab Injection
- Volunteers
- 338 people
- Sponsor
- Hansoh BioMedical R&D Company
NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity…
- Conditions
- NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage
- Trial name
- BActinium-2 (NCT07887971)
- Testing
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Aktis Oncology, Inc.
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung…
- Trial name
- EVOKE-SCLC-04 (NCT06801834)
- Testing
- Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only)
- Where
- 219 sites in United States, Argentina and 21 more
- Volunteers
- 695 people
- Sponsor
- Gilead Sciences
Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves…
- Trial name
- NCT07472517
- Testing
- obrixtamig, atezolizumab, carboplatin
- Where
- 245 sites in United States, Argentina and 40 more
- Volunteers
- 670 people
- Sponsor
- Boehringer Ingelheim
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and…
- Trial name
- NCT07564401
- Testing
- DJI136
- Where
- 7 sites in United States, Australia and 2 more
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
This is a single arm, multi-center clinical trial. The goal of this clinical trial is to evaluate the efficacy, safety and biomarkers of Tafolecimab combined with Sintilimab and Chemotherapy as first-line treatment for patients…
- Conditions
- Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
- Trial name
- STAR-SCLC (NCT07061535)
- Testing
- Tafolecimab, Sintilimab (approved), Etoposide
- Where
- 5 sites in China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Iadademstat + SBRT With Atezo in ES-SCLC
This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy with or without immune checkpoint inhibitor…
- Trial name
- TIARA (NCT07113691)
- Testing
- Iadademstat, Atezolizumab, SBRT
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Yale University
Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)
This study will evaluate the efficacy and safety of metronomic oral paclitaxel combined with a PD-1 or PD-L1 inhibitor as maintenance therapy in patients with advanced lung cancer whose disease has not progressed after first-line…
- Trial name
- PULSE (NCT07744698)
- Testing
- Paclitaxel Oral Solution, PD-1/PD-L1 inhibitor (eg. Tislelizumab)
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Anhui Provincial Cancer Hospital
Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
The goal of this clinical trial is to learn if the combination of sacituzumab govetican (SG) and atezolizumab/durvalumab is effective in controlling cancer tumor growth in adults with extensive stage small cell lung cancer.
- Trial name
- NCT07339059
- Testing
- Sacituzumab govitecan, Atezolizumab, Durvalumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Bindu R Potugari
Advanced or Metastatic Solid Tumors, Breast Cancer
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT05787587
- Testing
- IDE-161, Pembrolizumab
- Where
- 27 sites in United States
- Volunteers
- 216 people
- Sponsor
- IDEAYA Biosciences
Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC
This is a prospective, single-arm, investigator-initiated clinical study (IIT) designed to evaluate the efficacy and safety of nab-paclitaxel combined with local radiotherapy for patients with extensive-stage small cell lung…
- Trial name
- NCT07547332
- Testing
- Albumin-bound Paclitaxel Combined with Local Therapy, Albumin-Bound Paclitaxel /nab-Paclitaxel
- Volunteers
- 84 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
This is an single-arm, multicenter phase II study to evaluate the safety and efficacy of Sacituzumab Tirumotecan (sac-TMT) plus anlotinib in previously treated extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- STAR-01 (NCT07501169)
- Testing
- Sacituzumab Tirumotecan and Anlotinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sichuan University
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer
This study is a prospective, single arm, phase II clinical trial. We plan to include 36 newly diagnosed ES-SCLC patients who meet the inclusion criteria and receive induction therapy (tislelizumab+EP regimen, 4-6 cycles).
- Trial name
- NCT07425795
- Testing
- Tislelizumab Combined With Chemotherapy
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chongqing University Cancer Hospital
Extensive-stage Small Cell Lung Cancer (ES-SCLC), Thoracic Neoplasms
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC…
- Conditions
- Extensive-stage Small Cell Lung Cancer (ES-SCLC), Thoracic Neoplasms, Lung Neoplasms, Lung Diseases
- Trial name
- NCT06758700
- Testing
- Teniposide administration
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
A Study of Ivonescimab in First-Line ES-SCLC
The goal of this clinical trial is to learn if different combinations of a drug called Ivonescimab, along with chemotherapy and other investigational drugs, are safe and effective for the initial treatment of adults with…
- Trial name
- NCT07245446
- Testing
- Ivonescimab, Cadonilimab, AK117
- Where
- 3 sites in China
- Volunteers
- 180 people
- Sponsor
- Akeso
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
To explore the efficacy and safety of Tislelizumab combined with chemotherapy and relayed radiotherapy in the first-line treatment of extensive small cell lung cancer
- Trial name
- NCT06838208
- Testing
- Tislelizumab, Carboplatin /Cisplatin, Etoposide
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Anhui Provincial Cancer Hospital
Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive-stage Small Cell Lung Cancer (SCLC)
Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer
This study aims to provide personalized treatment options for patients with extensive-stage small cell lung cancer (SCLC) whose disease has worsened after initial chemotherapy.
- Conditions
- Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive-stage Small Cell Lung Cancer (SCLC), Small Cell Lung Cancer ( SCLC )
- Trial name
- NCT07106528
- Testing
- Organoid Drug Sensitivity Testing-Guided Therapy, Topotecan
- Volunteers
- 128 people
- Sponsor
- Peking Union Medical College Hospital
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
This study aims to investigate the clinical value of small extracellular vesicle (sEV) miRNAs as predictive biomarkers for immunochemotherapy efficacy in extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- NCT07070011
- Testing
- EC/EP + ICIs
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Shanghai Chest Hospital of Shanghai Jiao Tong University
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer
This is a Phase I clinical study of HS-20093. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of HS-20093 in combination with Adebrelimab in patients with Extensive Stage Small Cell Lung Cancer…
- Trial name
- NCT07063407
- Testing
- HS-20093 in combination with Adebrelimab
- Volunteers
- 50 people
- Sponsor
- Shanghai Hansoh Biomedical Co., Ltd
Extensive-stage Small Cell Lung Cancer (ES-SCLC), The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy
Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase
This study is a prospective, randomized, parallel-controlled clinical trial, aiming to evaluate the efficacy and safety of nano-crystalline megestrol acetate combined with standard treatment compared to standard treatment alone…
- Trial name
- NCT06961201
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, standard treatment
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.